What Can Your Expect at the Only Dedicated Forum for Neoantigen Therapeutics?
This highly focused conference unites all the key players in the neoantigen field from Europe and US across biotech and pharma organisations. It brings together C-level executives, directors, heads and scientists focused on cancer immunotherapy, clinical & preclinical development, antigen discovery and validation, bioinformatics and regulatory considerations. All of them share the goal of developing neoantigen‑targeted therapies – making this conference a must‑attend.
Over 3 jam-packed days , you’ll see why this year is a turning point for Neoantigen therapies through:
- Landmark clinical results that are reshaping confidence in the space
- Learning about how more programmes are entering or reporting from trials
- Seeing how the industry is shifting from innovation to proof of concept
…and much more!
Attend to understand what these results mean for your own pipeline.
Who Should Attend?
Learn where you fit in with this audience and an insight into what you will take away from the summit:
For Clinical Leaders
- Benchmark trial design & outcomes
- Understand real-world efficacy
For Discovery & Translational Teams
- Improve neoantigen selection and validation
- Bridge preclinical to clinical success
For Biotech Executives
- Evaluate where the field is heading
- Identify partners and competitors
What Makes the International Neoantigen Summit an Unmissable Opportunity For You?
Latest Data Shared
Hear updates on techniques for neoantigen validation and target selection like immunopeptidomics and HLA profiling to better understand mutated sequences and improve targeting to help ensure highly targeted neoantigen therapies.
Hear new data from companies like: Transgene, CellVax Therapeutics, Geneos Therapeutics and more.
6 Brand-New Speaking Companies
Hear from these new members of the speaker faculty, who will share their clinical and preclinical data to help you better understand the direction of neoantigen therapies. Learn how to successfully progress your therapies into clinical trials.
New speaking companies include: Black Canyon Bio, CellVax Therapeutics, Echo Immune, Epitopea Ltd, Khosen Bio, and Treos Bio.
3 In-Depth Workshops
Spanning discovery to clinical development, the intimate workshops will help you overcome challenges at all points of your neoantigen therapeutic development, including:
- AI and bioinformatics to support and improve neoantigen validation
- Clinical trial setup and operational planning
- Next‑generation neoantigen development, including novel modalities
- Exploration of future combination therapies
Hear from neoantigen experts from: Khosen Bio, Transgene, Erasmus MC, and Geneos Therapeutics.
Explore the Full Event Guide
- Accelerating precision immunotherapy by combining bioinformatics and AI to solve neoantigen validation bottlenecks, with insights from Khosen Bio and Transgene
- Enhancing personalised cancer vaccines through real‑world clinical learnings from Evaxion’s AI‑driven neoantigen immunotherapy platform
- Advancing DNA‑encoded neoantigen vaccines to drive robust immune responses in advanced cancer patients, featuring Nykode Therapeutics
- Unlocking the dark genome to discover novel targets for affordable, multi‑valent cancer immunotherapies, with Epitopea
- Scaling personalised neoantigen peptide immunotherapy for glioblastoma by optimising development and manufacturing pathways, with YGION Biomedical
Attending Companies Include
Explore the Agenda
Hear the latest industry breakthroughs and gain exclusive insights during our packed agenda, interactive roundtables, and panel discussions.
Partner With Us
Position yourself alongside other leading solution providers to ensure your brand is at the heart of biopharma deals.
Join Biopharma Experts
Be part of the hottest conversations with like-minded attendees spanning all stages of drug development and make critical connections during our dedicated networking sessions